ArticleTranslational andrology and urology2025
MSI2 exerts antitumor effects by regulating T-cell function in kidney renal clear cell carcinoma.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Musashi 2 (MSI2) exhibits oncogenic effects in various solid tumors. However, its mechanism of action in kidney renal clear cell carcinoma (KIRC) remains unclear. Our study objective is to explore the expression of MSI2 in KIRC and its relationship with the tumor microenvironment (TME). Methods: We analyzed MSI2 expression at the messenger ribonucleic acid (mRNA) and protein levels using the TIMER2.0 and University of Alabama at Birmingham Cancer Data Analysis Portal (UALCAN) databases, respectively. We also validated the expression and role of MSI2 in renal cells in cell-based experiments and examined the relationship between MSI2 expression and prognosis and the immune microenvironment. Furthermore, we performed an enrichment analysis and constructed regulatory networks for MSI2 to explore its functions and regulatory mechanisms. Finally, we conducted single-cell RNA sequencing (scRNA-seq) to identify key cells in KIRC and a pseudotemporal analysis to investigate their differentiation trajectories. Results: While MSI2 and its mRNA are typically upregulated in other cancers, they are downregulated in KIRC. A Kaplan-Meier (KM) analysis showed that KIRC patients with high MSI2 expression exhibited improved survival rates. MSI2 was mainly expressed in renal tubules in normal renal tissue and not in KIRC cells. Knocking down MSI2 promoted KIRC cell proliferation, invasion, and migration Conclusions: Our results suggest that MSI2 plays an antitumor role in KIRC by regulating T-cell function. They also indicate that MSI2 is involved in hydrogen ion secretion in renal tubular epithelial cells and that it may be a differentiation and maturation marker in these cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.